Panbela Announces Publication Of Preclinical And Clinical Data Titled: Inhibition Of Polyamine Biosynthesis Preserves β Cell Function In Type 1 Diabetes
Portfolio Pulse from Benzinga Newsdesk
Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the publication of preclinical and clinical data from studies of CPP-1X (DFMO) in recent onset type 1 diabetes (T1D). The data suggests that DFMO treatment may preserve β cell function and health in T1D. The research is part of a multi-site clinical trial led by Indiana University (IU) School of Medicine, supported by funding from JDRF. Panbela Therapeutics is providing the drug at no cost to researchers and was not involved in the design and analysis of these studies.
November 02, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The announcement of promising preclinical and clinical data for Panbela's CPP-1X (DFMO) in type 1 diabetes treatment could potentially boost investor confidence in the company's research and development capabilities.
The announcement of positive preclinical and clinical data for a company's drug candidate is typically seen as a positive development, as it suggests progress in the drug's development and increases the likelihood of eventual regulatory approval. This could potentially lead to increased investor confidence in Panbela and a positive impact on its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100